Listen & Subscribe
Choose your preferred player:
Question mark. For questions about subscriptions or your Slate Plus feed, etc..
For questions about subscriptions or your Slate Plus feed, check our FAQ.
Please enable javascript to get your Slate Plus feeds.
Get Your Slate Plus Podcast
If you can't access your feeds, please contact customer support.
Listen on your computer:
Apple Podcasts will only work on MacOS operating systems since Catalina. We do not support Android apps on desktop at this time.
Listen on your device:RECOMMENDED
These links will only work if you're on the device you listen to podcasts on.
question mark
We are showing you options for a computer but if you're on a phone or tablet We are showing you options for a phone or a tablet but if you're on a computer, click here. If you still have questions about subscriptions or your Slate Plus Feed, check our FAQ.
Loading...
We're sorry, but something went wrong while fetching your podcast feeds. Please contact us at plus@slate.com for help.
Episode Notes
Ketamine has gone from a recreational psychedelic to an approved treatment, and it has caught on in Silicon Valley in a big way. Are the long-term effects of using ketamine—recreationally or therapeutically—sufficiently known? Are we witnessing them right now?
Guest: Shayla Love, staff writer for the Atlantic.
Want more What Next TBD? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at slate.com/whatnextplus to get access wherever you listen.
Podcast production by Evan Campbell and Patrick Fort.